S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

BioSpecifics Technologies Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 12/2/2020)
Today's Range
Now: $88.53
50-Day Range
MA: $88.47
52-Week Range
Now: $88.53
Average Volume61,105 shs
Market Capitalization$650.25 million
P/E Ratio37.51
Dividend YieldN/A
BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.
BioSpecifics Technologies logo


Overall MarketRank

1.26 out of 5 stars

Medical Sector

642nd out of 1,556 stocks

Pharmaceutical Preparations Industry

327th out of 638 stocks

Analyst Opinion: 1.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BSTC



Sales & Book Value

Annual Sales$38.19 million
Cash Flow$3.38 per share
Book Value$18.42 per share


Net Income$24.47 million


Market Cap$650.25 million
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable

Receive BSTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BSTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BioSpecifics Technologies (NASDAQ:BSTC) Frequently Asked Questions

Is BioSpecifics Technologies a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSpecifics Technologies in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BioSpecifics Technologies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BSTC, but not buy additional shares or sell existing shares.
View analyst ratings for BioSpecifics Technologies
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than BioSpecifics Technologies?

Wall Street analysts have given BioSpecifics Technologies a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioSpecifics Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BioSpecifics Technologies' next earnings date?

BioSpecifics Technologies is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for BioSpecifics Technologies

How were BioSpecifics Technologies' earnings last quarter?

BioSpecifics Technologies Corp. (NASDAQ:BSTC) issued its earnings results on Saturday, November, 14th. The biopharmaceutical company reported $0.89 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.70. The biopharmaceutical company had revenue of $11.26 million for the quarter, compared to analyst estimates of $5.46 million. BioSpecifics Technologies had a net margin of 47.43% and a return on equity of 14.81%.
View BioSpecifics Technologies' earnings history

What price target have analysts set for BSTC?

1 brokerages have issued 1-year target prices for BioSpecifics Technologies' shares. Their forecasts range from $88.50 to $88.50. On average, they anticipate BioSpecifics Technologies' stock price to reach $88.50 in the next twelve months. This suggests that the stock has a possible downside of 0.0%.
View analysts' price targets for BioSpecifics Technologies
or view Wall Street analyst' top-rated stocks.

Who are some of BioSpecifics Technologies' key competitors?

What other stocks do shareholders of BioSpecifics Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioSpecifics Technologies investors own include AbbVie (ABBV), NVIDIA (NVDA), Pfizer (PFE), Biogen (BIIB), Johnson & Johnson (JNJ), Horizon Therapeutics Public (HZNP), Inovio Pharmaceuticals (INO), Intel (INTC), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

Who are BioSpecifics Technologies' key executives?

BioSpecifics Technologies' management team includes the following people:
  • Dr. Ronald Law J.D., Ph.D., Sr. VP of Bus. Devel. (Age 67, Pay $487.38k)
  • Mr. Joseph Truitt, CEO & Director (Age 55)
  • Mr. Patrick C. Hutchison, Chief Financial Officer (Age 61)
  • Mr. Alex Monteith, Sr. VP & Chief Bus. Officer
  • Carl A. Valenstein, Corp. Sec.

What is BioSpecifics Technologies' stock symbol?

BioSpecifics Technologies trades on the NASDAQ under the ticker symbol "BSTC."

What is BioSpecifics Technologies' stock price today?

One share of BSTC stock can currently be purchased for approximately $88.53.

How big of a company is BioSpecifics Technologies?

BioSpecifics Technologies has a market capitalization of $650.25 million and generates $38.19 million in revenue each year. The biopharmaceutical company earns $24.47 million in net income (profit) each year or $3.33 on an earnings per share basis. BioSpecifics Technologies employs 7 workers across the globe.

What is BioSpecifics Technologies' official website?

The official website for BioSpecifics Technologies is www.biospecifics.com.

How can I contact BioSpecifics Technologies?

BioSpecifics Technologies' mailing address is 2 Righter Parkway Suite 200, Wilmington DE, 19803. The biopharmaceutical company can be reached via phone at 302-842-8450 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.